Donepezil for Alzheimer's disease. (Q36972671)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17939763 AND SRC:MED&resulttype=core&format=json

8 January 2020

review article

1 reference

title

Donepezil for Alzheimer's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17939763 AND SRC:MED&resulttype=core&format=json

8 January 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17939763 AND SRC:MED&resulttype=core&format=json

8 January 2020

author name string

Boben Benjamin

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17939763 AND SRC:MED&resulttype=core&format=json

8 January 2020

publication date

1 October 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17939763 AND SRC:MED&resulttype=core&format=json

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

8 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17939763 AND SRC:MED&resulttype=core&format=json

8 January 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17939763 AND SRC:MED&resulttype=core&format=json

8 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17939763 AND SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

1243-1249

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17939763 AND SRC:MED&resulttype=core&format=json

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

8 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Therapeutic strategies for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Treatment of Alzheimer's disease: current status and new perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Stereoselective interactions of peptide inhibitors with the beta-amyloid peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Development of BACE1 inhibitors for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Glutamate-based therapeutic approaches: ampakines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Acetylcholinesterase inhibition in Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Chemical pathology of this organic dementias. II. Quantitative estimation of cellular changes in post-mortem brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Mechanisms of action of cognitive enhancers on neuroreceptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Preclinical evidence of neuroprotection by cholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Randomized, Placebo-Controlled Trial of the Effects of Donepezil on Neuronal Markers and Hippocampal Volumes in Alzheimer’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

PET imaging of brain acetylcholinesterase using [11C]CP-126,998, a brain selective enzyme inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Repeated dosing with donepezil does not affect the safety, tolerability or pharmacokinetics of single-dose thioridazine in young volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Concurrent administration of donepezil HCl and sertraline HCl in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Steady-state pharmacokinetics, pharmacodynamics and tolerability of donepezil hydrochloride in hepatically impaired patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Sex influences on cholinesterase inhibitor treatment in elderly individuals with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Vitamin E and donepezil for the treatment of mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Significance of syncope in patients with Alzheimer's disease treated with cholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Donepezil and cardiac syncope: case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Convulsions induced by donepezil

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

An update on pharmacological approaches to neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14737175.7.10.1243

10.1586/14737175.7.10.1243

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17939763 AND SRC:MED&resulttype=core&format=json

8 January 2020

1 reference